Patent search ap:("Genentech Page Inc.") AND inv:"Sanjeev Mariathasan"

11.

发明申请
METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY 审中-公开
Title translation: 使用抗PD-L1抗体及其用于增强T细胞功能以治疗肿瘤免疫的方法

公开(公告)号：US20140065135A1

公开(公告)日：2014-03-06

申请号：US13954796

申请日：2013-07-30

Applicant: Genentech, Inc.

Inventor： Bryan Irving , Henry Chiu , Heather Maecker , Sanjeev Mariathasan , Sophie M. Lehar , Yan Wu , Jeanne Cheung

IPC: C07K16/28 , A61K45/06 , A61K39/395 , A61K39/00

CPC classification number: C07K16/2827 , A61K31/7068 , A61K39/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/1063 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K2317/14 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/489 , Y02A50/492 , A61K2300/00

Abstract: The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及使用抗PD-L1抗体来增强T细胞功能以上调细胞介导的免疫应答和治疗T细胞功能障碍（包括感染（例如急性和慢性））和肿瘤免疫的方法。

12.

发明申请
ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF 审中-公开

公开(公告)号：US20180125995A1

公开(公告)日：2018-05-10

申请号：US15612193

申请日：2017-06-02

Applicant: Genentech, Inc.

Inventor： Eric Brown , Wouter Hazenbos , Isidro Hotzel , Kimberly Kajihara , Sophie M. Lehar , Sanjeev Mariathasan , Thomas Pillow , Leanna Staben , Vishal Verma , Binqing Wei , Yi Xia , Min Xu

IPC: A61K47/68 , C07K16/12 , A61K31/5383 , A61K45/06 , A61P31/04

CPC classification number: A61K47/6803 , A61K31/5383 , A61K45/06 , A61K47/6835 , A61K47/6889 , A61P31/04 , C07K16/1271 , C07K2317/21

Abstract: The invention provides rF1 antibody antibiotic conjugates and methods of using same.

13.

发明授权
Anti-PD-L1 antibodies, compositions and articles of manufacture 有权

公开(公告)号：US09920123B2

公开(公告)日：2018-03-20

申请号：US15335278

申请日：2016-10-26

Applicant: Genentech, Inc.

Inventor： Bryan Irving , Henry Chiu , Heather Maecker , Sanjeev Mariathasan , Sophie M. Lehar , Yan Wu , Jeanne Cheung

IPC: A61K39/00 , C07K16/28 , C07K16/30 , A61K31/7068 , A61K39/395 , A61K45/06 , C07K16/10 , C07K16/22

CPC classification number: C07K16/2827 , A61K31/7068 , A61K39/00 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/1063 , C07K16/22 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K2317/14 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/492 , A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

14.

发明授权
Anti-wall teichoic antibodies and conjugates 有权

公开(公告)号：US09884126B2

公开(公告)日：2018-02-06

申请号：US14284619

申请日：2014-05-22

Applicant: Genentech, Inc.

Inventor： Eric J. Brown , John Flygare , Wouter Hazenbos , Sophie M. Lehar , Sanjeev Mariathasan , John Hiroshi Morisaki , Thomas H. Pillow , Leanna Staben , Richard Vandlen , Klaus Koefoed , Magnus Strandh , Peter S. Andersen

IPC: A61K47/48 , C07K16/12 , A61K31/395 , A61K31/4375 , A61K31/439 , A61K31/4436 , A61K31/4709 , A61K31/7048 , A61K31/7056 , A61K38/12

CPC classification number: A61K47/6849 , A61K31/395 , A61K31/4375 , A61K31/439 , A61K31/4436 , A61K31/4709 , A61K31/7048 , A61K31/7056 , A61K38/12 , A61K47/6801 , A61K47/6803 , A61K47/6809 , A61K47/6835 , A61K47/6851 , C07K16/1271 , C07K2317/21 , C07K2317/522 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/624 , C07K2317/92

Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

15.

发明申请
ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF 审中-公开

公开(公告)号：US20180021450A1

公开(公告)日：2018-01-25

申请号：US15611985

申请日：2017-06-02

Applicant: Genentech, Inc.

Inventor： Eric Brown , Wouter Hazenbos , Isidro Hotzel , Kimberly Kajihara , Sophie M. Lehar , Sanjeev Mariathasan , Thomas Pillow , Leanna Staben , Vishal Verma , Binqing Wei , Min Xu

IPC: A61K47/68 , A61K31/4468 , A61K39/40 , A61K31/496

CPC classification number: A61K47/6809 , A61K31/4468 , A61K31/496 , A61K39/40 , A61K47/6803 , A61K47/6835 , A61K47/6889

Abstract: The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.

16.

发明授权
Gram-positive bacteria specific binding compounds 有权
Title translation: 革兰氏阳性菌特异性结合化合物

公开(公告)号：US09090677B2

公开(公告)日：2015-07-28

申请号：US13786215

申请日：2013-03-05

Applicant: Genentech, Inc. , AIMM Therapeutics B. V.

Inventor： Tim Beaumont , Mark Jeroen Kwakkenbos , Eric J. Brown , John Hiroshi Morisaki , Wouter L. W. Hazenbos , Sanjeev Mariathasan , Kimberly Kajihara , Yi Xia

IPC: C07H21/04 , C07K16/12

CPC classification number: G01N33/5091 , C07K16/1271 , C07K16/1278 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , G01N33/6854 , G01N33/6893 , G01N2469/10 , G01N2800/26

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract translation: 本发明提供能够特异性结合革兰氏阳性细菌的改进的结合化合物。提供了完全人类的结合化合物，可在人类个体中实现治疗应用。

17.

发明授权
Therapeutic and diagnostic methods for cancer 有权

公开(公告)号：US11535671B2

公开(公告)日：2022-12-27

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti Hegde , Marcin Kowanetz , Gregg Fine , Sanjeev Mariathasan , Richard Bourgon

IPC: C07K16/28 , C12Q1/6886 , G01N33/574 , A61K39/00

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

18.

发明申请
COMBINATION THERAPY FOR CANCER COMPRISING PD-1 AXIS BINDING ANTAGONIST AND IL6 ANTAGONIST 有权

公开(公告)号：US20210332143A1

公开(公告)日：2021-10-28

申请号：US17249530

申请日：2021-03-04

Applicant: Genentech, Inc.

Inventor： Mahrukh Huseni , Joanna E. Klementowicz , Yijin Li , Li-Fen Liu , Sanjeev Mariathasan , Mark Merchant , Luciana Molinero , Lifen Wang , Nathaniel West , Patrick Williams , Chi Yung Yuen , Edward Namserk Cha , Yulei Wang

IPC: C07K16/28 , A61P35/00 , A61K31/337 , A61K47/64

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.